Matches in SemOpenAlex for { <https://semopenalex.org/work/W80212804> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W80212804 abstract "Background: Therapeutic anti-Xa levels for enoxaparin (E) have been defined as 0.5–1.0 IU/mL. An increased hemmorhagic risk has been described at levels >1.5IU/mL. Current dosing recommendations for enoxaparin (E) do not account for age, gender, or creatinine clearance >30 ml/min. We have previously reported that a high number of elderly patients treated with standard dose E (1mg/kg subcutaneously every 12 hours) achieved suprathera-peutic Anti Xa levels. We compared a new E dosing strategy based on adjusted body weight (ABW) to these historical controls. Methods: We identified 50 consecutive patients greater than 65 years old (14 male, 36 female) admitted to our institution and treated with E for various clinical indications. Doses of E were calculated using ABW {ABW= (total body weight-ideal body weight)×0.4=ideal body weight}. Doses were rounded to the nearest 10mg. All patients had CrCl > 30mL/min. Blood samples for peak anti-Xa activity were obtained at steady state. Results were compared to patients receiving standard dose E Results: Subjects had a mean age of 76 ± 6 years, mean weight of 80 ± 18 kg, mean serum creatinine of 1.0 ± 0.2 mg/dL and a mean CrCl of 48 ± 8 mL/min. Thirty-three percent of patients were treated for atrial fibrillation ,27% for acute coronary syndrome, 20% for deep venous thrombosis/pulmonary embolism ,10% for CVA and 10% for Bridge Therapy. The mean anti-Xa activity was 0.93 ± 0.23 IU/mL. The range of anti-Xa activity was 0.42–1.31 IU/mL. Female patients received an average dose of 80% of their actual body weight; males received 88%. Conclusion: Thus, E dosing in elderly patients using adjusted body weight resulted in a significantly higher percentage of patients with anti-Xa levels within the therapeutic range and no patient with Anti-Xa levels above 1.5 IU/dL. (ABW dosing of E in patients > 65 yo may improve hemmorhagic risk associated with supratherapeutic E levels)." @default.
- W80212804 created "2016-06-24" @default.
- W80212804 creator A5017375514 @default.
- W80212804 creator A5030316622 @default.
- W80212804 creator A5055177157 @default.
- W80212804 creator A5078618151 @default.
- W80212804 date "2006-10-31" @default.
- W80212804 modified "2023-09-24" @default.
- W80212804 title "Abstract 1316: Enoxaparin Dosing in Elderly Patients Using Adjusted Body Weight" @default.
- W80212804 hasPublicationYear "2006" @default.
- W80212804 type Work @default.
- W80212804 sameAs 80212804 @default.
- W80212804 citedByCount "0" @default.
- W80212804 crossrefType "journal-article" @default.
- W80212804 hasAuthorship W80212804A5017375514 @default.
- W80212804 hasAuthorship W80212804A5030316622 @default.
- W80212804 hasAuthorship W80212804A5055177157 @default.
- W80212804 hasAuthorship W80212804A5078618151 @default.
- W80212804 hasConcept C126322002 @default.
- W80212804 hasConcept C141071460 @default.
- W80212804 hasConcept C147583825 @default.
- W80212804 hasConcept C159641895 @default.
- W80212804 hasConcept C2776265017 @default.
- W80212804 hasConcept C2777288759 @default.
- W80212804 hasConcept C2779161974 @default.
- W80212804 hasConcept C2780011451 @default.
- W80212804 hasConcept C2780306776 @default.
- W80212804 hasConcept C2780868729 @default.
- W80212804 hasConcept C42219234 @default.
- W80212804 hasConcept C71924100 @default.
- W80212804 hasConcept C90924648 @default.
- W80212804 hasConceptScore W80212804C126322002 @default.
- W80212804 hasConceptScore W80212804C141071460 @default.
- W80212804 hasConceptScore W80212804C147583825 @default.
- W80212804 hasConceptScore W80212804C159641895 @default.
- W80212804 hasConceptScore W80212804C2776265017 @default.
- W80212804 hasConceptScore W80212804C2777288759 @default.
- W80212804 hasConceptScore W80212804C2779161974 @default.
- W80212804 hasConceptScore W80212804C2780011451 @default.
- W80212804 hasConceptScore W80212804C2780306776 @default.
- W80212804 hasConceptScore W80212804C2780868729 @default.
- W80212804 hasConceptScore W80212804C42219234 @default.
- W80212804 hasConceptScore W80212804C71924100 @default.
- W80212804 hasConceptScore W80212804C90924648 @default.
- W80212804 hasLocation W802128041 @default.
- W80212804 hasOpenAccess W80212804 @default.
- W80212804 hasPrimaryLocation W802128041 @default.
- W80212804 hasRelatedWork W188241750 @default.
- W80212804 hasRelatedWork W1978819667 @default.
- W80212804 hasRelatedWork W2022448705 @default.
- W80212804 hasRelatedWork W2032668280 @default.
- W80212804 hasRelatedWork W2062628036 @default.
- W80212804 hasRelatedWork W2094656159 @default.
- W80212804 hasRelatedWork W2101337350 @default.
- W80212804 hasRelatedWork W2144130294 @default.
- W80212804 hasRelatedWork W2315024374 @default.
- W80212804 hasRelatedWork W2335176019 @default.
- W80212804 hasRelatedWork W2415473001 @default.
- W80212804 hasRelatedWork W2515726474 @default.
- W80212804 hasRelatedWork W2560807535 @default.
- W80212804 hasRelatedWork W2790734945 @default.
- W80212804 hasRelatedWork W2885485087 @default.
- W80212804 hasRelatedWork W2889229861 @default.
- W80212804 hasRelatedWork W2900514040 @default.
- W80212804 hasRelatedWork W2994502024 @default.
- W80212804 hasRelatedWork W3119809787 @default.
- W80212804 hasRelatedWork W3173003984 @default.
- W80212804 hasVolume "114" @default.
- W80212804 isParatext "false" @default.
- W80212804 isRetracted "false" @default.
- W80212804 magId "80212804" @default.
- W80212804 workType "article" @default.